{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:46:19Z","timestamp":1791081979157,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier","isbn-type":[{"value":"9780443470387","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB0570000"],"award-info":[{"award-number":["XDB0570000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471401"],"award-info":[{"award-number":["32471401"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.apha.2026.05.007","type":"book-chapter","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T11:49:12Z","timestamp":1779709752000},"page":"179-212","source":"Crossref","is-referenced-by-count":1,"title":["Transient T cell therapies"],"prefix":"10.1016","author":[{"given":"Yudian","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingliang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melgious Jin Yan","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.apha.2026.05.007_bib1","doi-asserted-by":"crossref","unstructured":"Adams, G. (2023). In vivo engineering of CAR T cells using a novel targeted LNP-mRNA technology., from 2023 https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.1202.","DOI":"10.1136\/jitc-2023-SITC2023.1202"},{"key":"10.1016\/bs.apha.2026.05.007_bib2","unstructured":"Aghajanian, H. (2025). A two-infusion regimen with a novel in vivo non-viral chimeric antigen receptor (CAR) achieves up to 90% CD8+ T cell engineering and tissue depletion of target cells in non-human primates (NHPs). In: ASGCT Annual Meeting Abstracts 258, from https:\/\/www.sciencedirect.com\/journal\/molecular-therapy\/vol\/33\/issue\/4\/suppl\/S1."},{"issue":"44","key":"10.1016\/bs.apha.2026.05.007_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202310395","article-title":"Spleen SORT LNP generated in situ CAR T cells extend survival in a mouse model of lymphoreplete B cell lymphoma","volume":"62","author":"\u00c1lvarez Benedicto","year":"2023","journal-title":"Angewandte Chemie International Edition"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.007_bib4","article-title":"1125 Preclinical development of MT-303, a novel LNP-formulated GPC3-specific CAR mRNA, for in vivo programming of monocytes to treat hepatocellular carcinoma","volume":"12","author":"Argueta","year":"2024","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.apha.2026.05.007_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1501365","article-title":"In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models","volume":"15","author":"Argueta","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.007_bib6","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala","year":"2024","journal-title":"Journal of Experimental Medicine"},{"issue":"10480","key":"10.1016\/bs.apha.2026.05.007_bib7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0140-6736(25)00039-X","article-title":"Assessing the oncogenic risk: The long-term safety of autologous chimeric antigen receptor T cells","volume":"405","author":"Baker","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.007_bib8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"10.1016\/bs.apha.2026.05.007_bib9","unstructured":"Becker, A. M. E. A. (2022). In situ CAR Therapy Using oRNATM Lipid Nanoparticles Regresses Tumors in Mice. In: SITC Annual Meeting, from https:\/\/www.ornatx.com\/wp-content\/uploads\/2022\/11\/Orna_SITC-2022.pdf."},{"issue":"1","key":"10.1016\/bs.apha.2026.05.007_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","article-title":"Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells","volume":"22","author":"Billingsley","year":"2022","journal-title":"Nano Letters"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.007_bib11","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Letters"},{"key":"10.1016\/bs.apha.2026.05.007_bib12","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","author":"Bot","year":"2025","journal-title":"Nature Reviews Drug Discovery"},{"issue":"16","key":"10.1016\/bs.apha.2026.05.007_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf1333","article-title":"A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells","volume":"7","author":"Bozza","year":"2021","journal-title":"Science Advances"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.007_bib14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.007_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-023-03586-1","article-title":"Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.007_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.tibtech.2024.07.017","article-title":"Harmonizing the symphony of chimeric antigen receptor T cell immunotherapy with the elegance of biomaterials","volume":"43","author":"Chen","year":"2025","journal-title":"Trends in Biotechnology"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.007_bib17","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","article-title":"Synergistic integration of mRNA-LNP with CAR-engineered immune cells: Pioneering progress in immunotherapy","volume":"32","author":"Chen","year":"2024","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.apha.2026.05.007_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"10.1016\/bs.apha.2026.05.007_bib19","unstructured":"Considerations for the development of chimeric antigen receptor (CAR) T cell products guidance for industry (2024). From https:\/\/www.fda.gov\/media\/156896\/download."},{"issue":"3","key":"10.1016\/bs.apha.2026.05.007_bib20","article-title":"Enhancing natural killer cells proliferation and cytotoxicity using imidazole-based lipid nanoparticles encapsulating interleukin-2 mRNA","volume":"35","author":"Delehedde","year":"2024","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.007_bib21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: Development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nature Reviews Drug Discovery"},{"issue":"18","key":"10.1016\/bs.apha.2026.05.007_bib22","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.007_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41571-021-00485-1","article-title":"Will allogeneic CAR T cells for CD19(+) malignancies take autologous CAR T cells \u2018off the shelf\u2019?","volume":"18","author":"DiNofia","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.apha.2026.05.007_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jconrel.2023.08.014","article-title":"Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells","volume":"361","author":"Douka","year":"2023","journal-title":"Journal of Controlled Release"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.007_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004450","article-title":"Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors","volume":"10","author":"Foster","year":"2022","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.apha.2026.05.007_bib26","unstructured":"Frantz, A. (2024). Profound B cell depletion and repopulation with predominantly na\u00efve B cells in non-human primates achieved through a novel in vivo CD8-targeted lipid nanoparticle mRNA CAR. In: American College of Rheumatology Annual Meeting 2026\/1\/20, 2026, from https:\/\/acrabstracts.org\/abstract\/profound-b-cell-depletion-and-repopulation-with-predominantly-naive-b-cells-in-non-human-primates-achieved-through-a-novel-in-vivo-cd8-targeted-lipid-nanoparticle-mrna-car\/."},{"key":"10.1016\/bs.apha.2026.05.007_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-025-00996-1","article-title":"International approvals of cilta-cel: A lens on CAR T cell regulation","author":"Ge","year":"2025","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.007_bib28","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3390\/biomedicines10112885","article-title":"An innovative PTD-IVT-mRNA delivery platform for CAR immunotherapy of ErbB(+) solid tumor neoplastic cells","volume":"10","author":"Georgiou-Siafis","year":"2022","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.007_bib29","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): A prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.apha.2026.05.007_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-67674-9","article-title":"Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy","author":"Gu","year":"2025","journal-title":"Nature Communications"},{"issue":"14","key":"10.1016\/bs.apha.2026.05.007_bib31","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood.2023021860","article-title":"BCMA-CAR T-cell treatment-associated parkinsonism","volume":"142","author":"Gust","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.007_bib32","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: An observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatology"},{"issue":"30","key":"10.1016\/bs.apha.2026.05.007_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202301515","article-title":"Ionizable lipid nanoparticles with integrated immune checkpoint inhibition for mRNA CAR T cell engineering","volume":"12","author":"Hamilton","year":"2023","journal-title":"Advanced Healthcare Materials"},{"key":"10.1016\/bs.apha.2026.05.007_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","author":"Hamilton","year":"2024","journal-title":"Nature Biotechnology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.007_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nature Communications"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.007_bib36","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"issue":"6753","key":"10.1016\/bs.apha.2026.05.007_bib37","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/bs.apha.2026.05.007_bib38","unstructured":"Hunter, T. (2024). A novel product candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles. In: American College of Rheumatology Annual Meeting 2026\/1\/20, 2026, from https:\/\/acrabstracts.org\/abstract\/a-novel-product-candidate-cptx2309-for-in-vivo-mrna-engineering-of-anti-cd19-car-t-cells-utilizing-novel-cd8-targeted-lipid-nanoparticles\/."},{"issue":"19","key":"10.1016\/bs.apha.2026.05.007_bib39","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1039\/D1LC00219H","article-title":"mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells","volume":"21","author":"Jayasooriya","year":"2021","journal-title":"Lab on a Chip"},{"issue":"43","key":"10.1016\/bs.apha.2026.05.007_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202103258","article-title":"Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Advanced Materials"},{"issue":"482","key":"10.1016\/bs.apha.2026.05.007_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Science Translational Medicine"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.007_bib42","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/ijms26030965","article-title":"Optimal chimeric antigen receptor (CAR)-mRNA for transient CAR T cell generation","volume":"26","author":"Kitte","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"issue":"3-4","key":"10.1016\/bs.apha.2026.05.007_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/hum.2019.194","article-title":"Differential transgene silencing of myeloid-specific promoters in the AAVS1 safe harbor locus of induced pluripotent stem cell-derived myeloid cells","volume":"31","author":"Klatt","year":"2020","journal-title":"Human Gene Therapy"},{"issue":"7949","key":"10.1016\/bs.apha.2026.05.007_bib44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: Design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.007_bib45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/bs.apha.2026.05.007_bib46","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2024-207566","article-title":"Vitro and in vivo activity of a lipid nanoparticle system for the in vivo generation of CAR T cells","volume":"144","author":"Lemgart","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.007_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10492","article-title":"Nanomaterials for mRNA-based therapeutics: Challenges and opportunities","volume":"8","author":"Li","year":"2023","journal-title":"Bioengineering & Translational Medicine"},{"key":"10.1016\/bs.apha.2026.05.007_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.007_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73755-0","article-title":"High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing","volume":"10","author":"Lissandrello","year":"2020","journal-title":"Scientific Reports"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.007_bib50","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/bs.apha.2026.05.007_bib51","article-title":"Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy","author":"Metzloff","year":"2024","journal-title":"Advanced Materials"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.007_bib52","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","article-title":"Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms","volume":"30","author":"Michels","year":"2022","journal-title":"Molecular Therapy"},{"issue":"7","key":"10.1016\/bs.apha.2026.05.007_bib53","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.apha.2026.05.007_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: The history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.007_bib55","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/leu.2016.180","article-title":"Enhanced CAR T-cell engineering using non-viral sleeping beauty transposition from minicircle vectors","volume":"31","author":"Monjezi","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/bs.apha.2026.05.007_bib56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/d41573-024-00150-z","article-title":"In vivo CAR T cells move into clinical trials [News]","volume":"23","author":"Mullard","year":"2024","journal-title":"Nature Reviews Drug Discovery"},{"issue":"9","key":"10.1016\/bs.apha.2026.05.007_bib57","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood.2025028375","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"146","author":"M\u00fcller","year":"2025","journal-title":"Blood"},{"key":"10.1016\/bs.apha.2026.05.007_bib58","unstructured":"Myeloid. (2023). Myeloid Therapeutics initiates patient dosing with MT-302, a novel TROP2-targeting RNA CAR, in phase 1 study for advanced or metastatic epithelial tumors [press release]. 2026\/1\/20, 2026, from https:\/\/createmedicines.com\/news\/myeloid-therapeutics-initiates-patient-dosing-with-mt-302-a-novel-trop2."},{"key":"10.1016\/bs.apha.2026.05.007_bib59","unstructured":"Myeloid. (2024). Myeloid Therapeutics initiates patient dosing with MT-303, a novel GPC3 targeting RNA CAR, in phase 1 study for advanced hepatocellular carcinoma (HCC) [press release]. 2026\/1\/20, 2026, from https:\/\/createmedicines.com\/news\/myeloid-therapeutics-initiates-patient-dosing-with-mt-303-a-novel-gpc3."},{"key":"10.1016\/bs.apha.2026.05.007_bib60","unstructured":"Myeloid. (2025). CREATE medicines announces Positive first-in-human results for MT-302 [press release]. 2026\/1\/20, 2026, from https:\/\/createmedicines.com\/news\/create-medicines-announces-positive-first-in-human-results-for-mt-302."},{"issue":"3","key":"10.1016\/bs.apha.2026.05.007_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030846","article-title":"Lentiviral vectors as a vaccine platform against infectious diseases","volume":"15","author":"Nemirov","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/bs.apha.2026.05.007_bib62","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","article-title":"CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model","volume":"29","author":"Ng","year":"2022","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/bs.apha.2026.05.007_bib63","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2018.02.043","article-title":"Cationic polymers for non-viral gene delivery to human T cells","volume":"282","author":"Olden","year":"2018","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/bs.apha.2026.05.007_bib64","unstructured":"Orna. (2026). Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting - Orna Therapeutics 2026\/1\/20, 2026, from https:\/\/www.ornatx.com\/orna-therapeutics-presents-new-data-supporting-its-in-vivo-car-programs-for-autoimmune-diseases-and-oncology-at-the-67th-american-society-of-hematology-annual-meeting\/."},{"issue":"1","key":"10.1016\/bs.apha.2026.05.007_bib65","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nature Communications"},{"issue":"4","key":"10.1016\/bs.apha.2026.05.007_bib66","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/bs.apha.2026.05.007_bib67","article-title":"CD19-targeting CAR T cell therapy in five patients with systemic sclerosis unsuitable for autologous stem cell transplantation","author":"Pecher","year":"2025","journal-title":"EULAR Rheumatology Open"},{"key":"10.1016\/bs.apha.2026.05.007_bib68","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jconrel.2022.11.038","article-title":"Polymer- and lipid-based gene delivery technology for CAR T cell therapy","volume":"353","author":"Pinto","year":"2023","journal-title":"Journal of Controlled Release"},{"issue":"15","key":"10.1016\/bs.apha.2026.05.007_bib69","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.007_bib70","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.cell.2023.02.031","article-title":"Delivering the next generation of cancer immunotherapies with RNA","volume":"186","author":"Raimondo","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.007_bib71","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03326-6","article-title":"Two for one: Targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells","volume":"20","author":"Roex","year":"2022","journal-title":"Journal of Translational Medicine"},{"issue":"6576","key":"10.1016\/bs.apha.2026.05.007_bib72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"17-18","key":"10.1016\/bs.apha.2026.05.007_bib73","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1089\/hum.2024.106","article-title":"Lipid nanoparticles for nucleic acid delivery beyond the liver","volume":"35","author":"Saber","year":"2024","journal-title":"Human Gene Therapy"},{"issue":"35","key":"10.1016\/bs.apha.2026.05.007_bib74","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/bs.apha.2026.05.007_bib75","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/JOM.0000000000000879","article-title":"Risks associated with lentiviral vector exposures and prevention strategies","volume":"58","author":"Schlimgen","year":"2016","journal-title":"Journal of Occupational and Environmental Medicine"},{"key":"10.1016\/bs.apha.2026.05.007_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"International Journal of Pharmaceutics"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.007_bib77","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ymthe.2025.01.024","article-title":"Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells","volume":"33","author":"Shankar","year":"2025","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.apha.2026.05.007_bib78","article-title":"Circular mRNA-based TCR-T offers a safe and effective therapeutic strategy for treatment of cytomegalovirus infection","author":"Shen","year":"2023","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.apha.2026.05.007_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202470164","article-title":"Enhancing CAR-NK cells against solid tumors through chemical and genetic fortification with DOTAP-functionalized lipid nanoparticles","author":"Shin","year":"2024","journal-title":"Advanced Functional Materials"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.007_bib80","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcyt.2023.01.005","article-title":"Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering","volume":"25","author":"Si","year":"2023","journal-title":"Cytotherapy"},{"issue":"21","key":"10.1016\/bs.apha.2026.05.007_bib81","article-title":"The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody","volume":"118","author":"Smith","year":"2021","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.007_bib82","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nature Nanotechnology"},{"issue":"21-22","key":"10.1016\/bs.apha.2026.05.007_bib83","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1089\/hum.2023.29255.pwl","article-title":"Integration of gene therapy vectors: A risk factor for tumorigenesis or another commensal property of adeno-associated viruses that benefits long-term transgene expression? [Editorial]","volume":"34","author":"Tai","year":"2023","journal-title":"Human Gene Therapy"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.007_bib84","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/acsnano.3c10109","article-title":"mRNA-laden lipid-nanoparticle-enabled in situ CAR-macrophage engineering for the eradication of multidrug-resistant bacteria in a sepsis mouse model","volume":"18","author":"Tang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/bs.apha.2026.05.007_bib85","first-page":"10","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: A randomized, double-blind, placebo-controlled phase 2b trial","author":"Vu","year":"2026","journal-title":"Nature Medicine"},{"issue":"15","key":"10.1016\/bs.apha.2026.05.007_bib86","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus [Letter]","volume":"393","author":"Wang","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"18","key":"10.1016\/bs.apha.2026.05.007_bib87","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.007_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102250","article-title":"Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Reports Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.007_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.celbio.2025.100011","article-title":"Leveraging T cell-specific fusogenicity of HIV for in vivo mRNA delivery to produce human CAR-T cells","volume":"1","author":"Wang","year":"2025","journal-title":"Cell Biomaterials"},{"issue":"3","key":"10.1016\/bs.apha.2026.05.007_bib90","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA circularization diminishes immunogenicity and can extend translation duration in vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Molecular Cell"},{"issue":"17","key":"10.1016\/bs.apha.2026.05.007_bib91","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1182\/bloodadvances.2020002355","article-title":"Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy","volume":"4","author":"Wilk","year":"2020","journal-title":"Blood Advances"},{"issue":"22","key":"10.1016\/bs.apha.2026.05.007_bib92","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1016\/j.cell.2025.07.046","article-title":"Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy","volume":"188","author":"Wu","year":"2025","journal-title":"Cell"},{"issue":"6","key":"10.1016\/bs.apha.2026.05.007_bib93","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Molecular Therapy"},{"issue":"11","key":"10.1016\/bs.apha.2026.05.007_bib94","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molmed.2025.05.011","article-title":"Technologies for chimeric antigen receptor transgene delivery","volume":"31","author":"Xiao","year":"2025","journal-title":"Trends in Molecular Medicine\u2019s"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.007_bib95","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/bs.apha.2026.05.007_bib96","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41422-025-01128-1","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus [Letter]","volume":"35","author":"Yang","year":"2025","journal-title":"Cell Research"},{"key":"10.1016\/bs.apha.2026.05.007_bib97","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"Journal of Controlled Release"},{"issue":"2","key":"10.1016\/bs.apha.2026.05.007_bib98","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/acsbiomaterials.1c01532","article-title":"In vitro engineering chimeric antigen receptor macrophages and T cells by lipid nanoparticle-mediated mRNA delivery","volume":"8","author":"Ye","year":"2022","journal-title":"ACS Biomaterials Science & Engineering"},{"key":"10.1016\/bs.apha.2026.05.007_bib99","article-title":"Development of an M1-polarized, non-viral chimeric antigen receptor macrophage (CAR-M) platform for cancer immunotherapy","author":"Yumi Ohtani., E. A","year":"2020","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"45","key":"10.1016\/bs.apha.2026.05.007_bib100","doi-asserted-by":"crossref","first-page":"41756","DOI":"10.1021\/jacs.5c13982","article-title":"Fluorinated ionizable lipids for efficient spleen-targeted mRNA delivery in cancer immunotherapy","volume":"147","author":"Zhang","year":"2025","journal-title":"Journal of the American Chemical Society"},{"issue":"1","key":"10.1016\/bs.apha.2026.05.007_bib101","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12896-018-0419-0","article-title":"Optimized DNA electroporation for primary human T cell engineering","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Biotechnology"},{"issue":"51","key":"10.1016\/bs.apha.2026.05.007_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303261","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Advanced Materials"}],"container-title":["Advances in Pharmacology","Pharmacology of T-Cell Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358926000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358926000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T22:44:01Z","timestamp":1785969841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358926000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443470387"],"references-count":102,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2026.05.007","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}